ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Trading Up 2.4% – Here’s Why

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO)’s share price traded up 2.4% during mid-day trading on Thursday . The stock traded as high as $65.01 and last traded at $64.90. Approximately 49,921 shares were traded during mid-day trading, an increase of 40% from the average daily volume of 35,636 shares. The stock had previously closed at $63.35.

ALPS Medical Breakthroughs ETF Stock Up 2.4%

The stock has a 50-day moving average of $55.08 and a 200 day moving average of $52.82.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

Several institutional investors have recently modified their holdings of SBIO. Exencial Wealth Advisors LLC grew its position in shares of ALPS Medical Breakthroughs ETF by 3.2% during the 4th quarter. Exencial Wealth Advisors LLC now owns 8,101 shares of the company’s stock worth $415,000 after buying an additional 248 shares during the period. Royal Bank of Canada lifted its holdings in ALPS Medical Breakthroughs ETF by 2.8% in the fourth quarter. Royal Bank of Canada now owns 12,269 shares of the company’s stock valued at $628,000 after buying an additional 330 shares during the period. McGuire Investment Group LLC boosted its stake in ALPS Medical Breakthroughs ETF by 5.9% in the fourth quarter. McGuire Investment Group LLC now owns 8,798 shares of the company’s stock valued at $451,000 after acquiring an additional 488 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new position in ALPS Medical Breakthroughs ETF in the fourth quarter valued at approximately $26,000. Finally, Griffin Asset Management Inc. boosted its stake in ALPS Medical Breakthroughs ETF by 1.9% in the fourth quarter. Griffin Asset Management Inc. now owns 30,699 shares of the company’s stock valued at $1,572,000 after acquiring an additional 564 shares during the last quarter.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.